Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification

Śmiech, Anna; Ślaska, Brygida; Łopuszyński, Wojciech; Jasik, Agnieszka; Bochyńska, Diana; Dąbrowski, Roman

doi:10.1186/s13028-018-0424-2

Cited by 29 publications

(45 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 and in median survival times. 29,31 Nonetheless, TT did deliver clinical benefit to 4 dogs in the study with high-grade MCT with enlarged locoregional LNs where metastasis was not confirmed on FNAs.…”

Section: Discussionmentioning

confidence: 89%

Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)

Ridder¹,

Campbell²,

Burke-Schwarz

et al. 2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of tigilanol tiglate (TT) for local intratumoral treatment of mast cell tumors (MCTs) in dogs. Methods A randomized controlled clinical study in 2 phases involving 123 dogs with cytologically diagnosed MCT. Phase 1 compared 81 TT‐treated dogs with 42 control dogs; phase 2 allowed TT treatment of control dogs and retreatment of dogs that failed to achieve tumor resolution after TT treatment in phase 1. Tigilanol tiglate (1 mg/mL) was injected intratumorally with dose based on tumor volume. Concomitant medications were used to minimize potential for MCT degranulation. Modified response evaluation criteria in solid tumors were used to evaluate treatment response at 28 and 84 days. Adverse events and quality of life were also assessed. Results A single TT treatment resulted in 75% complete response (CR) (95% confidence interval [CI] = 61‐86) by 28 days, with no recurrence in 93% (95% CI = 82‐97) of dogs by 84 days. Eight TT‐treated dogs that did not achieve CR in phase 1 achieved CR after retreatment, increasing the overall CR to 88% (95% CI = 77‐93). Control dogs had 5% CR (95% CI = 1‐17) at 28 days. Wound formation after tumor slough and wound size relative to tumor volume were strongly associated with efficacy. Adverse events typically were low grade, transient, and directly associated with TT's mode of action. Conclusions Tigilanol tiglate is efficacious and well tolerated, providing a new option for the local treatment of MCTs in dogs.

show abstract

Section: Discussionmentioning

confidence: 89%

Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)

Ridder¹,

Campbell²,

Burke-Schwarz

et al. 2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…The median age was 8.5 years, all the patients had been neutered and there was an even distribution of gender. There was an overrepresentation of medium to large dogs with Staffordshire Bull Terriers featuring prominently (46)(47)(48)(49). The number of patients in this study was limited by its retrospective nature, and the small sample size was too low for any definitive statistical analysis.…”

Section: Discussionmentioning

confidence: 93%

Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate

Brown¹,

Campbell²,

Jones³

et al. 2021

Front. Vet. Sci.

View full text Add to dashboard Cite

Canine high-grade mast cell tumours (HGMCT) are associated with a poor prognosis, are inherently more invasive, and have higher rates of local recurrence. The primary aim of this retrospective study was to assess the efficacy of intratumoural tigilanol tiglate (TT) as a local treatment option. Eighteen dogs with mast cell tumours (MCT) cytologically diagnosed by veterinary pathologists as either high-grade or suspected high-grade MCT were treated with TT. The TT dose was based on tumour volume (0.5 mg TT/cm3 tumour volume) and delivered intratumourally using a Luer lock syringe and a fanning technique to maximise distribution throughout the tumour mass. Efficacy was assessed on the presence/absence of a complete response (CR) to therapy at days 28 and 84 using response evaluation criteria in solid tumours (RECIST). For dogs not achieving a CR after 28 days, the protocol was repeated with a second intratumoural TT injection. Ten out of 18 dogs (56%) in this study achieved and maintained a CR to at least 84 days after their first or second treatment. Six patients were alive and available for evaluation at 2 years, three of those were recurrence free, and a further three patients were recurrence free following a second treatment cycle. Tigilanol tiglate shows efficacy for local treatment of HGMCT, with higher efficacy noted with a second injection if a CR was not achieved following the first treatment. In the event of treatment site recurrence (TSR), the tumour may be controlled with additional treatment cycles. Tigilanol tiglate provides an alternative local treatment approach to dogs with HGMCT that would either pose an unacceptable anaesthetic risk or the tumour location provides a challenge when attempting surgical excision.

show abstract

“…Śmiech et al . [ 20 ] classified 75.8% of MCTs as low intensity and 24.2% as high intensity. These results were similar to those of Hergt et al .…”

Section: Discussionmentioning

confidence: 99%

“…According to the Kiupel system, 56.17% (17/30) of samples were of low intensity and 43.33% (13/30) were of high intensity. Śmiech et al [20] classified 75.8% of MCTs as low intensity and 24.2% as high intensity. These results were similar to those of Hergt et al [21] who classified 74.46% of MCTs as low intensity and 25.54% as high intensity.…”

Section: Discussionmentioning

confidence: 99%

Histological classification and expression of markers of canine mast cell tumors

et al. 2020

View full text Add to dashboard Cite

Background and Aim: Mast cell tumors (MCTs) are malignant neoplasms that are common in dogs. Their biological behavior is variable and unpredictable. The aim of the present study was to analyze the histological classification and expression of markers of canine MCTs. Materials and Methods: Thirty samples of canine MCTs were graded according to the histological classification methods of Patnaik and those of Kiupel. The expression of phosphoprotein 53 (p53) and c-kit proteins was quantified by immunohistochemistry using image processing software, ImageJ - a public domain computer program, developed at the National Institutes of Health. Results: It was possible to determine the grade of 100% of the samples. According to Patnaik's classification, 20.00% of the samples were Grade 1, 43.30% were Grade 2, and 36.70% were Grade 3. According to Kiupel's classification, 56.67% of the samples were of high intensity and 43.33% were of low intensity. Grade 1 tumors had the highest expression of p53 and c-kit, and Grade 2 had the lowest expression. The results showed that it is necessary to perform both histological grading methods. The classification into high and low intensity may provide more consistent results than the three-level grading system. However, a smaller number of categories, although it facilitates the classification, may not be sufficient for the prognosis. Conclusion: Quantitative evaluation of p-53 and c-kit expression is a useful tool to increase the accuracy of the analysis and to aid in choosing the treatment method for canine MCTs. Histological grading should be combined with other diagnostic methods.

show abstract

Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification

Cited by 29 publications

References 40 publications

Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)

Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)

Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate

Histological classification and expression of markers of canine mast cell tumors

Contact Info

Product

Resources

About